Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer

Breast Cancer Clinical Trial

Official title:

Pyrotinib as Neoadjuvant Agent for Non-objective Response Patients of HER2-positive Early Breast Cancer Treated by Trastuzumab, Pertuzumab, and Chemotherapy (PYHOPE-BC-104): a Randomized, Controlled, Phase Ⅱ Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04717531
• Other study ID #: PYHOPE-BC-104
• Status: Recruiting
• Phase: Phase 2
• Start date: June 3, 2021
• Est. completion date: May 31, 2024

Study information

• Verified date: June 2021
• Source: The First Affiliated Hospital with Nanjing Medical University
• Contact: Jue Wang, MD
• Phone: 00862568308172
• Email: wangjue200011[@]njmu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study assesses the efficacy of neoadjuvant treatment with pyrotinib and trastuzumab with chemotherapy, mainly pathological complete response (pCR) rates in the breast and axilla.

And also assesses side effects, event-free survival (EFS), disease-free survival (DFS), distant disease-free survival (DDFS), and objective response rates (ORR).

Description:

Investigational Medical Products (IMPs) will be pyrotinib (B), trastuzumab (H), pertuzumab (P), docetaxel (T), epirubicin (E), and cyclophosphamide (C).

Magnetic resonance imaging (MRI) will be performed at baseline and 2 cycles after neoadjuvant therapy with trastuzumab, pertuzumab, and docetaxel (THP*2). Non-objective response patients will be randomly assigned (2:1) to receive 2 cycles of pyrotinib and trastuzumab with docetaxel followed by 4 cycles of pyrotinib and epirubicin plus cyclophosphamide (THB*2-ECB[epirubicine, cyclophosphamide, and pyrotinib]*4, cohort A), or 2 cycles of trastuzumab and pertuzumab with docetaxel followed by 4 cycles of epirubicin plus cyclophosphamide (THP*2-EC*4, cohort B).

During the neoadjuvant therapy, the side effects and all the events were recorded and analyzed. After surgery, the efficacy of pCR rate and ORR were analyzed. And long time follow-up will also be performed to analyze EFS, DFS, DDFS, and ORR.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: May 31, 2024
• Est. primary completion date: June 1, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Female patients between 18-70 years old. 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 3. Histologically confirmed HER2 (human epidermal growth factor receptor-2)-positive invasive breast cancer.

4. Non-objective response after 2 cycles of THP as neoadjuvant treatment. 5. Known hormone receptor status. 6. Patient has adequate bone marrow, liver, and renal function:

1. Hematological: White blood cell (WBC) count > 3.5 x 109/L, absolute neutrophil count (ANC) = 1.5 x 109/L, platelet count = 90 x109/L, and hemoglobin = 90 g/dL.

2. Hepatic function: total bilirubin = 1.5 x institutional upper limit of normal (ULN) (except for Gilbert's syndrome); aspartate transaminase (AST) and alanine transaminase (ALT) = 2.5 times ULN.

3. Renal function: serum creatinine and BUN = 1.5 x ULN, or creatinine clearance = 50 ml/min/1.73 m2 for patients with creatinine levels above institutional normal.

8. LVEF =50% measured by echocardiography. 9. Fertile patients must use effective contraception (barrier method - condoms, diaphragm - also in conjunction with spermicidal jelly, or total abstinence. Oral, injectable, or implant hormonal contraceptives are not allowed).

10. Negative serum pregnancy test, within 2-weeks (preferably 7 days) prior to randomization (For women of childbearing potential).

11. Signed informed consent form (ICF).

Exclusion Criteria:

1. Metastatic breast cancer;

2. Previous (less than 10 years) or current history of malignant neoplasms, except for curatively treated: Basal and squamous cell carcinoma of the skin; Carcinoma in situ of the cervix.

3. Patients with a prior malignancy diagnosed more than 10 years prior to randomization may enter the study. Patients must have been curatively treated with surgery alone. Radiation therapy or systemic therapy (chemotherapy or endocrine) are NOT permitted. Prior diagnoses of breast cancer or melanoma are excluded.

4. Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial;

5. Major surgical procedure or significant traumatic injury within 14 days prior to randomization or anticipation of the need for major surgery within the course of the study treatment.

6. Known history of uncontrolled or symptomatic angina, clinically significant arrhythmias, congestive heart failure, transmural myocardial infarction, uncontrolled hypertension (=180/110), unstable diabetes mellitus, dyspnoea at rest, or chronic therapy with oxygen;

7. Known hypersensitivity reaction to one of the investigational compounds or incorporated substances.

8. Pregnant or lactating patients. Patients of childbearing potential must implement adequate non-hormonal contraceptive measures during study treatment.

9. Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Pyrotinib
400mg, qd, po, day 1-21
• Trastuzumab
6 mg/kg, day 1
• Pertuzumab
420 mg, day 1
• Docetaxel
100 mg/m2, day 1
• Epirubicin
90mg/m2, day 1
• Cyclophosphamide
600 mg/m2, day 1

Locations

Country	Name	City	State
China	the First Affiliated Hospital of Nanjing Medical University	Nanjing	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
The First Affiliated Hospital with Nanjing Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pathological complete response (pCR) rate	Number of patients with pCR (no invasive breast cancer in the breast and axilla)	up to 30 weeks
Secondary	Number of patients with grade >3 adverse events as a measure of safety and tolerability	To describe the safety of the various regimens toxicity is compared between the two arms.	up to 30 weeks
Secondary	Objective response rate (ORR)	ORR is defined as the proportion of patients who achieved a complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.	up to 30 weeks
Secondary	Disease-free Survival (DFS)	DFS was defined as the time from surgery to the first date of breast cancer relapse, second primary tumor (including contralateral breast cancer), or death without documented prior relapse. Data will be reported when they are mature and available, likely when a median of 3 years follow up has been reached.	Following surgery, every 12 months until Year 10
Secondary	Event Free Survival (EFS)	EFS will be defined as the time from random assignment to documentation of the first of the following events: discontinuation of study therapy due to protocol-defined progression prior to surgery; local, regional, or distant recurrence of breast cancer following curative surgery; a new breast cancer; another new onset malignancy; or death as a result of any cause.	From date of randomization until follow-up to 10 years
Secondary	Distant-disease- free survival (DDFS)	DDFS is defined as the time period from randomization to the first event.	From date of randomization until follow-up to 10 years